UTHR to launch new pulmonary products; revenue target $50-100B
UTHR says new products aimed at pulmonary diseases are set to launch over the next few years, projecting $50–100 billion in annual revenue. Tyvaso and ralinepag are advancing through regulatory milestones.
Fourteen new products targeting pulmonary diseases are slated to launch over the next few years, with projected annual revenue of $50-100 billion. Key assets include Tyvaso and ralinepag, both advancing through regulatory milestones, alongside a major push into xenotransplantation, supported by robust financial backing.